Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

NervGen licenses Case Western Reserve technology to treat nerve damage


By Jesse Schwartz
Published: July 25th, 2018

NervGen Pharma Corp., a Vancouver-based company specializing in regenerative medicine, and Case Western Reserve University have entered into an exclusive worldwide licensing agreement to commercialize a technology that could lead to new therapies for spinal cord injury and other conditions caused by nerve damage.

Developed by Case Western researcher Jerry Silver, the technology targets a neural receptor known as protein tyrosine phosphatase sigma (PTPs) that inhibits nerve regeneration through scarred regions in spinal cord injury and other conditions. The drug candidate utilizes an agent called ISP to counter PTPs and promote regeneration of damaged nerves, a method that has shown promise in animal models.

Through the license agreement, NervGen aims to accelerate the ISP technology into the clinic to treat spinal cord injury while also leveraging the innovation to identify more therapeutic candidates for the treatment, including stroke, multiple sclerosis, peripheral nerve injury, and heart attack.

“We are extremely excited to be advancing this important nerve regeneration technology as there is currently no approved therapy known to enhance nerve regrowth in patients suffering from nerve damage,” says NervGen CEO Ernest Wong. “The functional recovery observed in animal models is unprecedented and consistent across multiple preclinical models in several independent university laboratories.”

NervGen will continue to collaborate with Silver and co-inventor Brad Lang, an executive-in-residence at BioEnterprise in Cleveland, OH, as it advances the technology through clinical development.

“We are very excited to work with NervGen to drive our PTPs program towards clinical testing as it holds the possibility of improving the lives of millions of spinal cord injury patients,” says Silver.

Source: GlobeNewswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment